Bicycle therapeutics announces pipeline progress update

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced progress updates for its wholly owned, next-generation bicycle toxin conjugates (btcs) targeting oncological indications, as well as its novel, fully synthetic bicycle tumor-targeted immune cell agonists (ticas™). “we are excited to start 2021 by an
BCYC Ratings Summary
BCYC Quant Ranking